主页
市场
图表与思路
Algo
新闻
Store
经纪商
下载
经济日历
交易信号
网页端
键入
/
进行搜索:@user,$symbol
查找
登录
创建账户
한국어
English
Русский
中文
Español
Português
日本語
Deutsch
Français
Italiano
Türkçe
FATE
#3071
Fate Therapeutics, Inc.
1.4
8
+2.07%
版块:
基础:
利润货币:
日范围
年范围
日变化
+2.07%
每月变动
+12.12%
6个月变化
+28.70%
年变化
+39.62%
前一天收盘价
1.4
5
Open
1.4
8
Bid
Ask
Low
1.4
8
High
1.4
8
交易量
50
市场
股票
医疗保健
FATE
Open full chart
Financials
Overview
声明
Statistics
Dividends
Quarterly
Annual
Value
2020
2021
2022
2023
2024
2025
TTM
Key stats
Total common shares outstanding
93.78 M
96.43 M
98.16 M
99.24 M
114.6 M
116.26 M
—
Valuation ratios
Enterprise value
8.36 B
5.51 B
936.98 M
324.32 M
153.03 M
67.62 M
305.92 M
Price to earnings ratio
—
—
-3.49
-2.25
-1.01
-0.85
-3.11
Price to sales ratio
—
—
10.23
5.72
13.76
—
—
Price to cash flow ratio
—
—
3.97
2.75
1.53
1.1
4.32
Price to book ratio
—
—
2.03
0.99
0.59
0.56
0.87
Enterprise value to EBITDA ratio
—
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.28
0.23
0.4
0.32
0.42
0.43
0.38
Return on equity %
0.45
0.31
0.58
0.44
0.58
0.66
0.55
Return on invested capital %
84.91
148.36
248.65
348.86
497.5
421.68
—
Gross margin %
100
100
100
100
100
100
400
Operating margin %
407.47
388.56
320.23
299.86
1 542.63
2 222.45
9 003.96
EBITDA margin %
—
—
—
—
—
—
—
Net margin %
551.59
379.89
292.55
253.3
1 366.46
2 051.08
8 313.2
Liquidity ratios
Quick ratio
—
—
—
—
—
—
—
Current ratio
5.78
7.79
4.4
8.48
7.58
5.79
30.51
Inventory turnover
—
—
—
—
—
—
—
Asset turnover
0.07
0.07
0.12
0.1
0.03
0.02
0.02
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
—
Long term debt to total assets ratio
—
—
—
—
—
—
—
Long term debt to total equity ratio
—
—
—
—
—
—
—
Per share metrics
Operating cash flow per share
—
—
2.56
1.34
1.08
0.89
0.89
EBIT per share
—
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
—
Cash per share
—
—
4.51
3.2
2.45
1.71
7.44
Net current asset value per share
—
—
5.19
3.37
2.57
1.76
7.66
Tangible book value per share
—
—
5
3.74
2.8
1.74
8.35
Working capital per share
—
—
4.01
2.97
2.23
1.45
6.64
Book value per share
—
—
5
3.74
2.8
1.74
8.35
新闻
Baird, Fate Therapeutics 투자의견 및 목표주가 유지
Baird reiterates Fate Therapeutics stock rating on trial progress
Fate Therapeutics (FATE) Reports Q4 Loss, Misses Revenue Estimates
Fate Therapeutics Q4 실적, 수익 예상치를 넘어
Fate Therapeutics earnings beat, revenue topped estimates
Fate Therapeutics reports positive lupus treatment data at ASH meeting
Fate Therapeutics Q3 실적, 수익 예상치를 넘어
Fate Therapeutics earnings beat by $0.03, revenue topped estimates
Fate Therapeutics (FATE) Reports Q3 Loss, Beats Revenue Estimates
Fate Therapeutics (FATE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
3 Cancer-Focused Stocks Showing Strong Pipeline Progress
Incyte (INCY) Tops Q3 Earnings and Revenue Estimates